The medical technology company launches a pilot study for a portable 12-lead ECG patch designed to help detect heart problems outside hospitals and clinics.
Austin, Texas, 18 May 2026 – Heart health monitoring may soon become easier, faster, and more accessible for millions of people living with cardiac conditions. HeartBeam has launched a new pilot study for its on-demand 12-lead ECG patch, a wearable device that could help patients monitor serious heart symptoms from home. The company aims to improve how coronary artery disease is detected and managed, especially when symptoms happen outside a hospital setting.
The pilot study will involve around 50 patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia. Researchers will compare readings from HeartBeam’s wearable patch with standard hospital ECG machines after patients complete exercise stress tests. The goal is to see how accurately the patch can capture heart activity during possible ischemic events, which occur when blood flow to the heart is reduced.
Unlike traditional ECG systems that require multiple wired connections and trained technicians, HeartBeam’s technology is designed to be portable and user-friendly. The company’s patch continuously monitors heart rhythm via a single-lead ECG. When patients experience symptoms such as chest pain, dizziness, or discomfort, they can activate a full, synthesized 12-lead ECG simply by touching the device with two fingers.
This approach could become a major advancement in digital healthcare and remote patient monitoring. Many heart-related symptoms appear suddenly and disappear before patients can reach a clinic or emergency room. Traditional wearable devices mainly focus on tracking heart rhythms, but HeartBeam is working to expand that capability to detect ischemia and other serious cardiac conditions in real time.
According to the company, the wearable cardiac monitoring market is already worth nearly $2 billion. Existing patch monitors are commonly used for arrhythmia tracking, but they are limited in providing deeper clinical insights. HeartBeam believes its 3D ECG technology could fill this gap by offering clinical-grade heart data beyond basic rhythm analysis.
The company has already received FDA clearance for its 3D ECG technology for arrhythmia assessment in 2024 and for its 12-lead ECG synthesis software in 2025. Its growing focus on AI-powered healthcare solutions and portable diagnostics reflects a larger trend in the health technology industry where wearable medical devices are becoming more advanced and patient-centered.
HeartBeam’s latest study also highlights the growing role of smart wearable devices in preventive healthcare. With cardiovascular diseases remaining one of the leading causes of death globally, innovations that support faster diagnosis and early intervention could help improve patient outcomes and reduce hospital burden.
If the pilot study delivers strong results, the technology could eventually provide patients with faster access to heart monitoring wherever they are, whether at home, work, or while traveling. For people living with ongoing cardiac risks, that convenience could make a meaningful difference in receiving timely care.